Oxeia Biopharma
Company profile on P2PMarketData. Oxeia Biopharma is a biotechnology company based in Boston, MA, founded in 2014. It has raised $2.3M through crowdfunding on StartEngine.
Oxeia Biopharma is a biotechnology company based in Boston, Massachusetts that develops treatments for concussion recovery. The company is advancing OXE103, a ghrelin-based therapy designed to address post-concussion syndrome, for which no FDA-approved treatments currently exist. The company's approach is supported by clinical data and collaboration with existing research on ghrelin therapies.
Frequently asked questions about Oxeia Biopharma
How much funding has Oxeia Biopharma raised?
Oxeia Biopharma has raised $2.3M through crowdfunding across 1 round tracked by P2PMarketData, from 850 investors.
What is Oxeia Biopharma's valuation?
Oxeia Biopharma had an indicative valuation of $50M in its 2026 funding round.
Is Oxeia Biopharma profitable?
No. Oxeia Biopharma reported a net loss of $1.2M for fiscal year 2024.
How many employees does Oxeia Biopharma have?
Oxeia Biopharma reported 2 employees for fiscal year 2024.
When was Oxeia Biopharma founded?
Oxeia Biopharma was founded in March 2014.
Where is Oxeia Biopharma based?
Oxeia Biopharma is headquartered in Boston, Massachusetts, United States, and is incorporated in Delaware, United States.
What industry is Oxeia Biopharma in?
Oxeia Biopharma operates in the Biotechnology industry within the Healthcare sector.